Recent Updates
Recently added Catalysts
KYTX Positive Sentiment

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

Wednesday, May 28, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Kyverna Therapeutics will present at the Jefferies Global Healthcare Conference on June 4, 2025. CEO Warner Biddle will discuss the company's advancements in cell therapies for autoimmune diseases. The presentation will be accessible via a live webcast, with a replay available for 30 days. Kyverna's lead candidate, KYV-101, is in late-stage clinical development.
Price reaction · baseline $2.55 (2025-05-28 close) · hit after-hours · clean, no other KYTX news in the window
day 0 close · peak
+3.1%

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • Kyverna is actively developing innovative cell therapies.
  • The company is advancing its lead CAR T-cell therapy candidate, KYV-101.
  • Kyverna is participating in a prominent healthcare conference.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+37%
120-day peak, hindsight
Typical move
5%
average across 6 past catalysts
Cash runway
~15 mo
Low dilution risk
Lead asset
KYV-101 anti-CD19 CAR-T cell therapy
Phase 1 · Multiple Sclerosis

Full Press Release Details

EMERYVILLE, Calif.,May 28, 2025/PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced thatWarner Biddle, Chief Executive Officer of Kyverna, will present at the Jefferies Global Healthcare Conference inNew York, NYonWednesday, June 4, 2025, at4:55 p.m. ET.
A live webcast of the presentation may be accessed via the Investors section of the Kyverna website atir.kyvernatx.com. A replay of the webcast will be available on the website for 30 days following the conference.

About Kyverna TherapeuticsKyverna Therapeutics, Inc. (Nasdaq:KYTX) is a clinical-stage biopharmaceutical company focused on liberating patients through the curative potential of cell therapy. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through late-stage clinical development with registrational trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase 1/2 trials for patients with lupus nephritis.  The Company is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis, to inform the next priority indications for the Company to advance into late-stage development.  Its pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.  For more information, please visithttps://kyvernatx.com.

Contact:Investors:[email protected]Media:[email protected]

Frequently Asked Questions

When will Kyverna present at the Jefferies Conference?

Kyverna will present on June 4, 2025, at 4:55 p.m. ET.

Who will represent Kyverna at the conference?

CEO Warner Biddle will represent Kyverna Therapeutics.

How can I access the presentation?

The presentation can be accessed via a live webcast on Kyverna's website.

What is Kyverna's lead therapy candidate?

Kyverna's lead candidate is KYV-101, a CAR T-cell therapy.

What diseases does Kyverna focus on?

Kyverna focuses on developing therapies for autoimmune diseases.

ShareAdd on Google
Tags: KYTX Viatris Investor Conferences Healthcare Kyverna Therapeutics cell therapies autoimmune diseases Jefferies Global Healthcare Conference
Last updated: May 28, 2025

Conference Timeline

Nov 11, 2025
UBS Global Healthcare Conference
8:45 AM ET • Fireside Chat
Nov 18, 2025
Jefferies Global Healthcare
11:30 AM GMT • London

Biotech snapshot

Cash runway
$199M liquidity · $13M/mo burn
~15 mo
Low dilution risk
Lead asset
KYV-101 anti-CD19 CAR-T cell therapyPhase 1
Multiple Sclerosis →

Catalyst track record

+37%
best trade around KYTX's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for KYTX.

See every catalyst's timing & PoA →